MARKET

BSX

BSX

Boston Scient
NYSE

Real-time Quotes | Nasdaq Last Sale

38.68
-0.09
-0.22%
Opening 12:07 03/03 EST
OPEN
38.74
PREV CLOSE
38.76
HIGH
38.90
LOW
38.31
VOLUME
2.29M
TURNOVER
--
52 WEEK HIGH
42.37
52 WEEK LOW
24.10
MARKET CAP
54.81B
P/E (TTM)
-474.5399
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
Zacks.com · 2h ago
The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 2)
Benzinga · 4h ago
The Global Peripheral Nerve Stimulators Market is expected to grow by $ 141.03 mn during 2021-2025 progressing at a CAGR of 5% during the forecast period
GlobeNewswire · 4h ago
Boston Scientific to acquire surgical business of Lumenis for $1 billion cash
Boston Scientific (BSX) has entered into an agreement with Baring Private Equity Asia to acquire the global surgical business of Lumenis LTD. (LUME) for an upfront cash payment of $1.07B, subject to
Seekingalpha · 4h ago
8-K: BOSTON SCIENTIFIC CORP
(EDGAR Online via COMTEX) -- 0000885725 false 0000885725 2021-03-03 2021-03-03 0000885725 us-gaap:CommonStockMember 2021-03-03 2021-03-03...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4h ago
DJ Boston Scientific Buys Surgical Business to Expand Kidney Stone Management Portfolio
Dow Jones · 4h ago
UPDATE 1-Boston Scientific to buy surgical business of Lumenis for $1.07 bln
reuters.com · 4h ago
Boston Scientific to spend $1.1 billion in cash to buy Lumentis LTD's surgical business
Boston Scientific Corp. undefined announced Wednesday an agreement to buy the global surgical business of Lumenis LTD for $1.07 billion in cash from Baring...
marketwatch.com · 5h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BSX. Analyze the recent business situations of Boston Scient through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 27 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BSX stock price target is 43.36 with a high estimate of 50.00 and a low estimate of 39.00.
EPS
Institutional Holdings
Institutions: 1.24K
Institutional Holdings: 1.40B
% Owned: 98.57%
Shares Outstanding: 1.42B
TypeInstitutionsShares
Increased
318
138.97M
New
203
-11.63M
Decreased
280
167.02M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-1.71%
Healthcare Equipment & Supplies
-1.45%
Key Executives
Chairman/President/Chief Executive Officer/Director
Michael Mahoney
Chief Financial Officer/Executive Vice President
Daniel Brennan
Executive Vice President
Arthur Butcher
Executive Vice President
Joseph Fitzgerald
Executive Vice President
Edward Mackey
Executive Vice President
Ian Meredith
Executive Vice President
Jeffrey Mirviss
Executive Vice President
David Pierce
Executive Vice President
Eric Thepaut
Senior Vice President/Chief Information Officer
Jodi Eddy
Senior Vice President/General Counsel/Secretary
Desiree Ralls-Morrison
Senior Vice President/Director of Human Resources
Wendy Carruthers
Senior Vice President
Maulik Nanavaty
Senior Vice President
Scott Olson
Senior Vice President
Meghan Scanlon
Senior Vice President
John Sorenson
Lead Director/Independent Director
Edward Ludwig
Independent Director
Nelda Connors
Independent Director
Charles Dockendorff
Independent Director
Yoshiaki Fujimori
Independent Director
Donna James
Independent Director
Stephen MacMillan
Independent Director
Stephen Macmillan
Independent Director
David Roux
Independent Director
John Sununu
Independent Director
Ellen Zane
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About BSX
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Webull offers kinds of Boston Scientific Corporation stock information, including NYSE:BSX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BSX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BSX stock methods without spending real money on the virtual paper trading platform.